The multi-specialty chain, Ahmedabad-based Shalby Hospital, decided to go for a big expansion plan establishing a pan India presence.
Merck's Phase 3 HIV trial highlights expertise in antiviral science, authority in clinical research, and advancing effective treatments showing minimal metabolic impact and reaffirming Merck's commitment to evidence-based HIV care
Indegene today unveiled its ambitious expansion of the Consulting Practice, reaffirming its ongoing commitment to enable life sciences organizations to navigate value and risk in large transformation efforts, in a complex, technology-driven world...
Iberia Pharmaceuticals, a leading name in skincare, has launched KeyCi, a science-backed skincare brand designed for modern consumers aged 18–45. KeyCi offers high-performance, dermatologically tested products that are vegan, cruelty-free...
Strides Pharma Science Limited today announced that one of its step-down wholly owned subsidiary will market the world’s first WHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Africa, strengthening...
Pfizer has disclosed positive Phase 3 results from the HER2CLIMB-05 trial, which is an important advancement for patients with HER2-positive (HER2+) metastatic breast cancer (MBC)...
Novo Nordisk has made a significant advance in the rare disease sector by signing a definitive asset purchase and license agreement with Omeros Corporation to acquire its clinical-stage MASP-3 inhibitor zaltenibart...
BASF has introduced Lutavit A/D3 1000/200 NXT, an advanced vitamin formulation that integrates vitamins A and D3 into one microencapsulated product. Representing BASF’s reentry into the market, this new solution offers enhanced efficiency, ease of us
Fortis Hospital, Mulund, has inaugurated its Fortis Cancer Institute and Institute of GastroSciences, marking a significant milestone in its mission to deliver comprehensive, patient-first healthcare.
Aragen, a prominent global contract research, development, and manufacturing organization (CRDMO), has announced the appointment of Neeraj Garg as Chief Executive Officer of its Discovery Solutions division
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")